Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738679) titled 'Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors' on July 21.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Condition: Advanced Solid Tumors

Intervention: Drug: TQB3454 tablets

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 2026

Target Sample Size: 127

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/s...